Expression of PD-1 and Tim-3 is increased in skin of patients with bullous pemphigoid and pemphigus vulgaris

被引:10
|
作者
Ernst, N. [1 ,2 ,3 ]
Friedrich, M. [3 ,4 ]
Bieber, K. [1 ,2 ]
Kasperkiewicz, M. [3 ,5 ]
Gross, N. [1 ,2 ,3 ]
Sadik, C. D. [2 ,3 ]
Zillikens, D. [2 ,3 ]
Schmidt, E. [1 ,2 ,3 ]
Ludwig, R. J. [1 ,2 ]
Hartmann, K. [3 ,6 ,7 ]
机构
[1] Univ Lubeck, Luebeck Inst Expt Dermatol, Lubeck, Germany
[2] Univ Lubeck, Ctr Res Inflammat Skin, Lubeck, Germany
[3] Univ Lubeck, Dept Dermatol, Lubeck, Germany
[4] Bernhard Nocht Inst Trop Med, Lab Emerging Infect, Hamburg, Germany
[5] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90007 USA
[6] Univ Basel, Div Allergy, Dept Dermatol, Basel, Switzerland
[7] Univ Basel, Dept Biomed, Basel, Switzerland
关键词
CELLS;
D O I
10.1111/jdv.16780
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Bullous pemphigoid (BP) and pemphigus vulgaris (PV) are common autoimmune bullous dermatoses (AIBD) characterized by blisters and erosions. Treatment options are limited and often insufficient. Immune checkpoint receptors play critical roles in immune homoeostasis and self- tolerance. Targeting checkpoint receptors is highly efficient in treatment of various cancers, but often also associated with autoimmune side effects. Objectives We therefore aimed to investigate the expression of immune checkpoint receptors in patients with BP and PV. Methods We analysed expression of the checkpoint receptors programmed cell death protein 1 (PD-1), T-cell immunoglobulin and mucin domain 3 (Tim-3) and lymphocyte activation gene 3 (Lag-3) in lesional skin of patients with BP and PV compared to healthy control skin as well as the expression patterns of PD-1 and Tim-3 on various infiltrating immune cells in skin sections of AIBD by immunohistochemistry and immunofluorescence. We also measured serum levels of soluble PD-1, Tim-3 and Lag-3 in AIBD patients by ELISA. Results We report on increased expression of PD-1 and Tim-3, but not Lag-3, in lesional skin of patients with BP and PV. Investigating the expression pattern of PD-1 and Tim-3 on different cutaneous immune cells, we observed significant upregulation of PD-1 predominantly on infiltrating CD8 T cells and upregulation of Tim-3 on CD8 T cells as well as macrophages. Conclusions Our results suggest exploring immune checkpoint receptors as novel therapeutic targets using an agonistic approach in autoimmune bullous diseases.
引用
收藏
页码:486 / 492
页数:7
相关论文
共 50 条
  • [21] Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in patients with vitiligo; positive association with disease activity
    Rahimi, Ali
    Hossein-Nataj, Hadi
    Hajheydari, Zohreh
    Aryanian, Zeinab
    Shayannia, Asghar
    Ajami, Abolghasem
    Asgarian-Omran, Hossein
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (06) : 674 - 681
  • [22] Increased TOX expression concurrent with PD-1, Tim-3, and CD244 in T cells from patients with non-Hodgkin lymphoma
    Huang, Shuxin
    Liang, Chaofeng
    Zhao, Yujie
    Deng, Tairan
    Tan, Jiaxiong
    Lu, Yuhong
    Liu, Sichu
    Li, Yangqiu
    Chen, Shaohua
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (01) : 143 - 149
  • [23] TIM-3 AND PD-1 ARE DIFFERENTLY EXPRESSED ON EXHAUSTED T CELLS IN HIV INFECTED PATIENTS
    Leitner, J.
    Rieger, A.
    Pickl, W.
    Zlabinger, G.
    Grabmeier-Pfistershammer, K.
    Steinberger, P.
    SEXUALLY TRANSMITTED INFECTIONS, 2013, 89 : A86 - A86
  • [24] Tim-3 and PD-1 are differently expressed on exhausted T cells in HIV infected patients
    Grabmeier-Pfistershammer, K.
    Leitner, J.
    Rieger, A.
    Steinberger, P.
    IMMUNOLOGY, 2012, 137 : 208 - 208
  • [25] Simultaneous measurement and significance of PD-1, LAG-3 and TIM-3 expression in human solid tumors
    Morgado, Micaela
    Datar, Ila
    Wang, Jun
    Sanmamed, Miguel F.
    McEachern, Kristen
    Jenkins, David
    Chen, Lieping
    Carvajal-Hausdorf, Daniel
    Rimm, David L.
    Herbst, Roy S.
    Schalper, Kurt A.
    CANCER RESEARCH, 2018, 78 (13)
  • [26] Expression and function of PD-1 and TIM-3 in non-small cell lung cancer (NSCLC)
    Travers, Jonathan
    McEachern, Krtisten
    Ghosh, Srimoyee
    Ramaswamy, Sridhar
    Jenkins, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [27] PD-1 AND Tim-3 EXPRESSION ON DIFFERENT SUBPOPULATIONS OF MONOCYTES IN CHRONIC OFTEN RECURRENT HERPESVIRUS INFECTION
    Rashchupkin, I. M.
    Meledina, I. V.
    Kotova, M. A.
    Zheltova, O. I.
    INFEKTSIYA I IMMUNITET, 2024, 14 (03): : 575 - 580
  • [28] Characterization of age-associated exhausted CD8+ T cells defined by increased expression of Tim-3 and PD-1
    Lee, Kyoo-A
    Shin, Kwang-Soo
    Kim, Ga-Young
    Song, You Chan
    Bae, Eun-Ah
    Kim, Il-Kyu
    Koh, Choong-Hyun
    Kang, Chang-Yuil
    AGING CELL, 2016, 15 (02) : 291 - 300
  • [29] A bivalent Tim-3/PD-1 bispecific antibody for the treatment of PD-1 antibody resistant or refractory NSCLC.
    Liu, Jiajian
    Luan, Y.
    Deng, H.
    Wang, F.
    Wang, C.
    Zhang, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Elevated Expression of Tim-3 and PD-1 Immune Checkpoint Receptors on T-CD4+ Lymphocytes of Patients with Asthma
    Mosayebian, Ali
    Koohini, Zohreh
    Hossein-Nataj, Hadi
    Abediankenari, Saeid
    Abedi, Siavash
    Asgarian-Omran, Hossein
    IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2018, 17 (06) : 517 - 525